Sweden's Cantargia narrows H1 loss, raises SEK 132 mln
Sweden's Cantargia narrows H1 loss, raises SEK 132 mln
Overview
Sweden biotechnology firm's H1 net sales were SEK 0.6 mln, net loss SEK 65.8 mln
Company raised SEK 132 mln via rights issue and loan facility to fund clinical development
Early positive results reported in ongoing hematology trial; clinical pipeline advancing
Outlook
Cantargia plans to initiate Phase 1b combination study in PDAC within next nine to twelve months
Company continues to enroll patients in MDS/AML study, aiming for data to support late-stage decisions
Cantargia advancing preclinical work on bispecific antibodies and antibody–drug conjugates for future therapies
Result Drivers
HEMATOLOGY TRIAL RESULTS - Early positive results reported from ongoing Phase 1b/2a trial in high-risk MDS and AML
CLINICAL PIPELINE PROGRESS - Continued enrollment in MDS/AML study and advancement in preclinical programs targeting IL1RAP
FINANCING SECURED - Rights issue and loan facility raised SEK 132 mln to fund clinical development activities
Company press release: ID:nMFN4F84Mj
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
H1 Sales |
| SEK 600,000 |
|
H1 Adjusted Loss Per Share |
| SEK 0.26 |
|
H1 Net Loss |
| SEK 65.80 mln |
|
H1 EBIT |
| -SEK 72.70 mln |
|
H1 Investments |
| SEK 12 mln |
|
Reuters Recommended Reads
Aug 17 - Cancer immunotherapy developer CEL-SCI's Q3 net loss unchanged
Aug 18 - Germany's Immatics Q2 revenue rises but misses estimates
Aug 17 - Fulcrum to merge with Slate in all-stock deal after drug setback
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)